Cancer Medicine (Apr 2023)

Characteristics and outcomes of gallbladder cancer patients at the Tata Medical Center, Kolkata 2017–2019

  • Anindita Dutta,
  • Tushar Mungle,
  • Nandita Chowdhury,
  • Pritha Banerjee,
  • Anisha Gehani,
  • Saugata Sen,
  • Mohandas Mallath,
  • Paromita Roy,
  • Shekhar Krishnan,
  • Sandip Ganguly,
  • Sudeep Banerjee,
  • Manas Roy,
  • Vaskar Saha

DOI
https://doi.org/10.1002/cam4.5677
Journal volume & issue
Vol. 12, no. 8
pp. 9293 – 9302

Abstract

Read online

Abstract Background The north and north‐eastern regions of India have among the highest incidence of gallbladder cancer (GBC) in the world. We report the clinicopathological charateristics and outcome of GBC patients in India. Methods Electronic medical records of patients diagnosed with GBC at Tata Medical Center, Kolkata between 2017 and 2019 were analyzed. Results There were 698 cases of confirmed GBC with a median age of 58 (IQR: 50–65) years and female:male ratio of 1.96. At presentation, 91% (496/544) had stage III/IV disease and 30% (189/640) had incidental GBC. The 2‐year overall survival (OS) was 100% (95% CI: 100–100); 61% (95% CI: 45–83); 30% (95% CI: 21–43); and 9% (95% CI: 6–13) for stages I–IV, respectively (p = <0.0001). For all patients, the 2‐year OS in patients who had a radical cholecystectomy followed by adjuvant therapy (N = 36) was 50% (95% CI: 39–64), compared to 29% (95% CI: 22–38) for those who had a simple cholecystectomy and/or chemotherapy (N = 265) and 9% (95% CI: 6–14) in patients who were palliated (N = 107) (p = <0.0001). Conclusion The combined surgical/chemotherapy approach for patients with stage II GBC showed the best outcomes. Early detection of GBC remains problematic with the majority of patients presenting with stage III–IV and who have a median survival of 9.1 months. Our data suggests that the tumor is chemoresponsive and multi‐center collaborative clinical trials to identify alternative therapies are urgently required.

Keywords